Addyi (Flibanserin) in Children Under 12: Off-Label Use, Safety, and Why It Has No Role in Pediatric Care

What Is Flibanserin and Who Is It Approved For?

Flibanserin is a non-hormonal, centrally acting drug approved by the FDA on June 18, 2015, under NDA 022526, for the treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal adult women. The label is narrow on purpose. The FDA rejected two earlier submissions in 2010 and 2013 before approving the drug with a Risk Evaluation and Mitigation Strategy (REMS) program. No pediatric indication exists, and the approved labeling contains no dosing section for patients under 18.

How the Drug Works

Flibanserin acts primarily as a serotonin 1A (5-HT1A) agonist and a serotonin 2A (5-HT2A) antagonist, with weaker antagonist activity at dopamine D4 receptors. This combination is thought to shift the balance of excitatory and inhibitory neurotransmitters in the prefrontal cortex, increasing dopamine and norepinephrine while reducing serotonin in that region. That mechanism is relevant to pediatric safety discussions because the prefrontal cortex continues maturing until approximately age 25, meaning any agent that modifies its dopaminergic or serotonergic tone during development carries theoretical risks that have never been studied in children.

The Approved Dose and Route

The approved adult dose is 100 mg taken orally at bedtime. Bedtime administration is not a convenience recommendation. It is a safety requirement: daytime dosing increases the risk of hypotension, syncope, and accidental injury. Even in adults, the drug's prescribing information notes that somnolence occurred in 11% of patients in the Phase 3 trials at 100 mg vs. 4% placebo. [1]

Why Off-Label Use in Children Under 12 Has No Evidentiary Basis

Children under 12 do not have HSDD. The diagnosis itself, as defined in DSM-5 (now separated into Male Hypoactive Sexual Desire Disorder and Female Sexual Interest/Arousal Disorder for adults), is not applicable to prepubertal children. Sexual desire as a biologically driven, hormonally mediated experience does not develop until puberty, which for most children begins between ages 8 and 13. Prescribing a drug designed to modulate adult sexual neurobiology in a prepubertal child lacks any diagnostic framework, let alone a pharmacological rationale.

No Pediatric Pharmacokinetic Data

The FDA's pediatric labeling database confirms that no pediatric pharmacokinetic studies have been conducted for flibanserin. The drug is metabolized primarily by CYP3A4 and, to a lesser extent, by CYP2C19. Children under 12 have CYP enzyme expression profiles that differ meaningfully from adults, which affects both peak plasma concentration (Cmax) and area under the curve (AUC). Without pediatric PK data, no safe dose can be calculated for this age group.

The FDA's own pediatric labeling guidance under the Pediatric Research Equity Act (PREA) requires sponsors to conduct pediatric studies when a drug is likely to be used in children. The flibanserin sponsor was explicitly exempted from this requirement because the approved indication, HSDD in premenopausal adults, has no pediatric analog. [2]

No Registered Trials in Pediatric Populations

A search of ClinicalTrials.gov on July 14, 2025, returns zero interventional trials of flibanserin in patients under 18. The three key Phase 3 trials that supported FDA approval, VIOLET (N=1,378), DAISY (N=1,091), and BEGONIA (N=949), enrolled only adult women aged 18 and older. No extrapolation from these data to pediatric populations is scientifically defensible. [3]

The Black-Box Warning and What It Means for a Child's Physiology

The FDA requires a black-box warning on flibanserin labeling for severe hypotension and syncope. This risk is substantially amplified by alcohol consumption and by co-administration of moderate or strong CYP3A4 inhibitors such as fluconazole, ketoconazole, or clarithromycin. Even without those interactions, the drug produced orthostatic hypotension in controlled trials.

Cardiovascular Considerations in Prepubertal Children

Children under 12 have lower mean arterial blood pressure than adults. A drug that produces clinically significant blood pressure drops in adults with normal baseline pressures would be expected to produce proportionally greater hemodynamic instability in a child. No pediatric cardiovascular safety data for flibanserin exist. The absence of data is not a green light; it is a stop sign.

CNS Development and Serotonergic Agents

Serotonin plays a well-documented role in brain development beyond its function as a neurotransmitter in adult mood and behavior. Animal studies with serotonergic agents during critical developmental windows have shown changes in synaptic density, receptor expression, and behavioral outcomes in offspring. [4] Whether flibanserin's specific 5-HT1A agonism and 5-HT2A antagonism would produce similar effects in a developing human brain is completely unknown, because those studies have not been done.

The American Academy of Pediatrics has broadly cautioned against the off-label use of CNS-active agents in children without strong pediatric-specific safety data, a principle directly applicable here. [5]

Regulatory and Ethical Framework Governing Off-Label Pediatric Prescribing

Off-label prescribing is legal in the United States and is common in pediatrics, where many drugs lack pediatric labeling. However, the standard for ethical off-label use requires some rational basis, whether mechanistic plausibility, case-series evidence, or published expert consensus. Flibanserin in children under 12 meets none of those criteria.

REMS as an Additional Barrier

Flibanserin's REMS program requires that prescribers, pharmacies, and patients all be enrolled through the Addyi REMS program. The program's certification process includes mandatory counseling on alcohol abstinence during treatment. A prescriber who attempted to enroll a child under 12 in the REMS program would find no mechanism to do so: the program was designed exclusively for adult women. Dispensing flibanserin to a child outside of the REMS framework would constitute a REMS violation under 21 U.S.C. § 355-1. [6]

Informed Consent and Assent Considerations

In pediatric medicine, any intervention requires parental informed consent and, for children capable of understanding, patient assent. Given that no risk-benefit data exist for this drug in children, meaningful informed consent is impossible. A parent cannot be told the probability of harm or benefit because those probabilities are empirically undefined.

The HealthRX clinical team has developed the following decision framework for clinicians who receive inquiries about flibanserin in pediatric patients:

1. Confirm the clinical question being asked. Is the concern about low sexual desire, a behavior, a psychiatric symptom, or something else entirely?
2. If a child under 12 is presenting with concerning changes in sexual behavior or interest, the appropriate referral is to pediatric psychology, child psychiatry, or developmental pediatrics, not to pharmacotherapy targeting adult sexual neurobiology.
3. Document clearly that flibanserin was considered and declined on the grounds of no pediatric indication, no safety data, and no diagnostic applicability.
4. If the inquiry originates from a caregiver who read about flibanserin online, provide written educational materials explaining the FDA's approved indication and the reasons why the drug is not appropriate for children.

What Clinicians Should Do Instead

Children under 12 who present with concerns that might superficially seem related to sexual desire or behavior require a completely different clinical pathway than adult HSDD management.

Differential Diagnosis in Prepubertal Children

Changes in sexual behavior in prepubertal children are evaluated in the context of normal psychosexual development, trauma screening, abuse assessment, and neurodevelopmental evaluation. The American Academy of Child and Adolescent Psychiatry (AACAP) practice parameters provide guidance on age-appropriate sexual behavior and the clinical red flags that warrant formal evaluation. No pharmacological agent targeting adult sexual desire has any role in this assessment.

Appropriate Referral Pathways

A child under 12 with behavioral concerns in this area should be referred to:

• A board-certified child and adolescent psychiatrist for formal psychiatric assessment.
• A pediatric psychologist with training in psychosexual development.
• A child protective services consultation if abuse is suspected, consistent with mandatory reporting obligations in all 50 U.S. States.

Addressing Precocious Puberty Separately

Occasionally, clinicians or caregivers conflate early puberty with adult sexual desire in a way that prompts questions about adult sexual pharmacology. Precocious puberty (defined as puberty beginning before age 8 in girls and age 9 in boys) is a recognized endocrine condition managed with GnRH analogs such as leuprolide acetate. [7] It has no treatment relationship with flibanserin. If precocious puberty is suspected, the appropriate referral is to pediatric endocrinology.

Summary of the Evidence Gap

The absence of evidence for flibanserin in children under 12 is not a minor gap waiting to be filled by future research. It reflects the complete absence of any clinical rationale for studying the drug in that population. The diagnostic category HSDD does not apply to prepubertal children. The CNS targets of flibanserin are not relevant to any recognized pediatric condition. The pharmacokinetic profile has never been characterized in pediatric patients, and no regulatory or professional body has suggested it should be.

The FDA's prescribing information states directly: "The safety and effectiveness of Addyi in pediatric patients have not been established." [1] That sentence ends the clinical question.

Clinicians encountering requests for off-label flibanserin in children under 12 should decline to prescribe, document their reasoning, and direct families to appropriate pediatric specialty care. If a child's presenting concern involves changes in sexual behavior or development, the diagnostic and therapeutic response belongs in pediatric psychiatry, developmental pediatrics, or pediatric endocrinology, not in adult sexual medicine pharmacology.

The FDA's REMS program for flibanserin requires a signed patient-provider agreement confirming that the patient is an adult woman. That agreement cannot be executed for a child, making any attempt to dispense the drug through legitimate pharmacy channels to a patient under 18 a regulatory violation, not merely a clinical judgment call.